|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
104 a.a.
|
 |
|
|
|
|
|
|
|
88 a.a.
|
 |
|
|
|
|
|
|
|
150 a.a.
|
 |
|
|
|
|
|
|
|
18 a.a.
|
 |
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Gene regulation
|
 |
|
Title:
|
 |
Crystal structure of a hydroxylated hif-1 alpha peptide bound to the pvhl/elongin-c/elongin-b complex
|
|
Structure:
|
 |
Elongin b. Chain: a. Synonym: transcription elongation factor b, polypeptide 2. Engineered: yes. Elongin c. Chain: b. Fragment: residues 17-112. Synonym: transcription elongation factor b (siii), polypeptide 1.
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Expressed in: escherichia coli bl21(de3). Expression_system_taxid: 469008. Synthetic: yes. Other_details: the peptide was synthesized with a biotin tag at the n-terminus and with p564 as a 4(r) hydroxyproline. The sequence of the peptide is naturally
|
|
Biol. unit:
|
 |
Tetramer (from
)
|
|
Resolution:
|
 |
|
2.00Å
|
R-factor:
|
0.225
|
R-free:
|
0.277
|
|
|
Authors:
|
 |
W.C.Hon,M.I.Wilson,K.Harlos,T.D.Claridge,C.J.Schofield, C.W.Pugh,P.H.Maxwell,P.J.Ratcliffe,D.I.Stuart,E.Y.Jones
|
Key ref:
|
 |
W.C.Hon
et al.
(2002).
Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL.
Nature,
417,
975-978.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
09-May-02
|
Release date:
|
03-Jul-02
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
|
|
|
Q15370
(ELOB_HUMAN) -
Transcription elongation factor B polypeptide 2
|
|
|
|
Seq: Struc:
|
 |
 |
 |
118 a.a.
104 a.a.
|
|
|
|
|
|
|
 |
 |
|
|
|
|
Q15369
(ELOC_HUMAN) -
Transcription elongation factor B polypeptide 1
|
|
|
|
Seq: Struc:
|
 |
 |
 |
112 a.a.
88 a.a.
|
|
|
|
|
|
|
 |
 |
|
 |
|
 |
|
 |
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
|
 |
|
Cellular component
|
nucleus
|
3 terms
|
 |
|
Biological process
|
protein complex assembly
|
6 terms
|
 |
|
Biochemical function
|
protein binding
|
1 term
|
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Nature
417:975-978
(2002)
|
|
PubMed id:
|
|
|
|
|
| |
|
Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL.
|
|
W.C.Hon,
M.I.Wilson,
K.Harlos,
T.D.Claridge,
C.J.Schofield,
C.W.Pugh,
P.H.Maxwell,
P.J.Ratcliffe,
D.I.Stuart,
E.Y.Jones.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Hypoxia-inducible factor-1 (HIF-1) is a transcriptional complex that controls
cellular and systemic homeostatic responses to oxygen availability. HIF-1 alpha
is the oxygen-regulated subunit of HIF-1, an alpha beta heterodimeric complex.
HIF-1 alpha is stable in hypoxia, but in the presence of oxygen it is targeted
for proteasomal degradation by the ubiquitination complex pVHL, the protein of
the von Hippel Lindau (VHL) tumour suppressor gene and a component of an E3
ubiquitin ligase complex. Capture of HIF-1 alpha by pVHL is regulated by
hydroxylation of specific prolyl residues in two functionally independent
regions of HIF-1 alpha. The crystal structure of a hydroxylated HIF-1 alpha
peptide bound to VCB (pVHL, elongins C and B) and solution binding assays reveal
a single, conserved hydroxyproline-binding pocket in pVHL. Optimized hydrogen
bonding to the buried hydroxyprolyl group confers precise discrimination between
hydroxylated and unmodified prolyl residues. This mechanism provides a new focus
for development of therapeutic agents to modulate cellular responses to hypoxia.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 2.
Figure 2: Structure of VCB -CODD complex, and sequence
alignments of HIF ODD regions and pVHL. a, b, Surface
rendering of the VCB -CODD complex with the secondary structures
revealed underneath the semitransparent surface. Two regions
seen in the current structure but not included in the previously
reported model of apo VCB^15 are circled in elongin B (residues
99 -104) and pVHL (residues 205 -210). The C-terminal tail of
elongin B makes newly observed contacts with the domain
(V170 and N174) of pVHL. The still-unobserved region (residues
50 -57) in elongin C is modelled as a dotted loop. c, d,
Sequence alignments of the CODD-binding region of pVHL domain
(c) and of the ODD motifs of HIF homologues (d). Residues that
form van der Waals (VDW) contacts are indicated by 'v'. 'w'
denotes single hydrogen bonds (H-bonds) formed with a key water
molecule (see Fig. 3d), as opposed to those formed between pVHL
and CODD (see Fig. 3a, b). Arrows denote -strands.
VHL disease missense mutations17 that occur in the CODD-binding
region of pVHL are listed.
|
 |
Figure 3.
Figure 3: CODD -pVHL interactions. a, b, Views of site 1 (a)
and site 2 (b). CODD and CODD-contacting residues of pVHL are
shown as stick models (colour scheme as in Fig. 1), whereas
pVHL, elongin C and elongin B are rendered as van der Waals
surfaces using the colour scheme of Fig. 2. Dotted lines
represent electrostatic bonds. Residues for pVHL are labelled in
white; those for CODD are in black. c, Views of the Hyp-binding
pocket, illustrating its surface complementarity. The van der
Waals surface of the ODD motif, LAHyp, is rendered solid and
coloured by atom type (as in Fig. 1). The surface of pVHL is
rendered as a mesh object with both the front and rear planes
clipped away. Inset, side view of Hyp. d, The hydrogen-bonding
network involved in binding of the Hyp564 hydroxyl group. The
side chain of L562 (CODD) has been omitted for clarity. The red
sphere in a, c and d represents a key water molecule. a has an
approximately similar orientation to that of Fig. 2a, whereas
the view in b is rotated from that in a by 70 degrees about the
vertical axis.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Macmillan Publishers Ltd:
Nature
(2002,
417,
975-978)
copyright 2002.
|
|
| |
Figures were
selected
by the author.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
C.Loenarz,
and
C.J.Schofield
(2011).
Physiological and biochemical aspects of hydroxylations and demethylations catalyzed by human 2-oxoglutarate oxygenases.
|
| |
Trends Biochem Sci, 36,
7.
|
 |
|
|
|
|
 |
D.M.Duda,
D.C.Scott,
M.F.Calabrese,
E.S.Zimmerman,
N.Zheng,
and
B.A.Schulman
(2011).
Structural regulation of cullin-RING ubiquitin ligase complexes.
|
| |
Curr Opin Struct Biol, 21,
257-264.
|
 |
|
|
|
|
 |
L.E.Glover,
and
S.P.Colgan
(2011).
Hypoxia and metabolic factors that influence inflammatory bowel disease pathogenesis.
|
| |
Gastroenterology, 140,
1748-1755.
|
 |
|
|
|
|
 |
K.L.Gorres,
and
R.T.Raines
(2010).
Prolyl 4-hydroxylase.
|
| |
Crit Rev Biochem Mol Biol, 45,
106-124.
|
 |
|
|
|
|
 |
M.M.Hou,
J.J.Hsieh,
N.J.Chang,
H.Y.Huang,
H.M.Wang,
C.K.Chuang,
T.Hsu,
and
J.W.Chang
(2010).
Response to sorafenib in a patient with metastatic xp11 translocation renal cell carcinoma.
|
| |
Clin Drug Investig, 30,
799-804.
|
 |
|
|
|
|
 |
R.Bekeredjian,
C.B.Walton,
K.A.MacCannell,
J.Ecker,
F.Kruse,
J.T.Outten,
D.Sutcliffe,
R.D.Gerard,
R.K.Bruick,
and
R.V.Shohet
(2010).
Conditional HIF-1alpha expression produces a reversible cardiomyopathy.
|
| |
PLoS One, 5,
e11693.
|
 |
|
|
|
|
 |
R.van Wijk,
S.Sutherland,
A.C.Van Wesel,
E.G.Huizinga,
M.J.Percy,
M.Bierings,
and
F.S.Lee
(2010).
Erythrocytosis associated with a novel missense mutation in the HIF2A gene.
|
| |
Haematologica, 95,
829-832.
|
 |
|
|
|
|
 |
T.Miyata,
and
C.Y.de Strihou
(2010).
Diabetic nephropathy: a disorder of oxygen metabolism?
|
| |
Nat Rev Nephrol, 6,
83-95.
|
 |
|
|
|
|
 |
B.E.Rendon,
S.S.Willer,
W.Zundel,
and
R.A.Mitchell
(2009).
Mechanisms of macrophage migration inhibitory factor (MIF)-dependent tumor microenvironmental adaptation.
|
| |
Exp Mol Pathol, 86,
180-185.
|
 |
|
|
|
|
 |
C.M.Lee,
M.M.Hickey,
C.A.Sanford,
C.G.McGuire,
C.L.Cowey,
M.C.Simon,
and
W.K.Rathmell
(2009).
VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo.
|
| |
Oncogene, 28,
1694-1705.
|
 |
|
|
|
|
 |
D.G.Fujimori
(2009).
Hypoxia sensing goes gauche.
|
| |
Nat Chem Biol, 5,
202-203.
|
 |
|
|
|
|
 |
D.M.Katschinski
(2009).
In vivo functions of the prolyl-4-hydroxylase domain oxygen sensors: direct route to the treatment of anaemia and the protection of ischaemic tissues.
|
| |
Acta Physiol (Oxf), 195,
407-414.
|
 |
|
|
|
|
 |
J.R.Forman,
C.L.Worth,
G.R.Bickerton,
T.G.Eisen,
and
T.L.Blundell
(2009).
Structural bioinformatics mutation analysis reveals genotype-phenotype correlations in von Hippel-Lindau disease and suggests molecular mechanisms of tumorigenesis.
|
| |
Proteins, 77,
84-96.
|
 |
|
|
|
|
 |
K.Knauth,
E.Cartwright,
S.Freund,
M.Bycroft,
and
A.Buchberger
(2009).
VHL Mutations Linked to Type 2C von Hippel-Lindau Disease Cause Extensive Structural Perturbations in pVHL.
|
| |
J Biol Chem, 284,
10514-10522.
|
 |
|
|
|
|
 |
K.Nakayama,
J.Qi,
and
Z.Ronai
(2009).
The ubiquitin ligase Siah2 and the hypoxia response.
|
| |
Mol Cancer Res, 7,
443-451.
|
 |
|
|
|
|
 |
L.Chen,
A.Endler,
and
F.Shibasaki
(2009).
Hypoxia and angiogenesis: regulation of hypoxia-inducible factors via novel binding factors.
|
| |
Exp Mol Med, 41,
849-857.
|
 |
|
|
|
|
 |
L.F.Kontovinis,
K.T.Papazisis,
P.Touplikioti,
C.Andreadis,
D.Mouratidou,
and
A.H.Kortsaris
(2009).
Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers.
|
| |
BMC Cancer, 9,
82.
|
 |
|
|
|
|
 |
L.Xie,
K.Xiao,
E.J.Whalen,
M.T.Forrester,
R.S.Freeman,
G.Fong,
S.P.Gygi,
R.J.Lefkowitz,
and
J.S.Stamler
(2009).
Oxygen-regulated beta(2)-adrenergic receptor hydroxylation by EGLN3 and ubiquitylation by pVHL.
|
| |
Sci Signal, 2,
ra33.
|
 |
|
|
|
|
 |
M.K.Koski,
R.Hieta,
M.Hirsilä,
A.Rönkä,
J.Myllyharju,
and
R.K.Wierenga
(2009).
The crystal structure of an algal prolyl 4-hydroxylase complexed with a proline-rich peptide reveals a novel buried tripeptide binding motif.
|
| |
J Biol Chem, 284,
25290-25301.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
M.T.Kuo
(2009).
Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities.
|
| |
Antioxid Redox Signal, 11,
99.
|
 |
|
|
|
|
 |
P.W.Furlow,
M.J.Percy,
S.Sutherland,
C.Bierl,
M.F.McMullin,
S.R.Master,
T.R.Lappin,
and
F.S.Lee
(2009).
Erythrocytosis-associated HIF-2alpha mutations demonstrate a critical role for residues C-terminal to the hydroxylacceptor proline.
|
| |
J Biol Chem, 284,
9050-9058.
|
 |
|
|
|
|
 |
R.Chowdhury,
M.A.McDonough,
J.Mecinović,
C.Loenarz,
E.Flashman,
K.S.Hewitson,
C.Domene,
and
C.J.Schofield
(2009).
Structural basis for binding of hypoxia-inducible factor to the oxygen-sensing prolyl hydroxylases.
|
| |
Structure, 17,
981-989.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
S.M.Chen,
Y.G.Li,
D.M.Wang,
G.H.Zhang,
and
C.J.Tan
(2009).
Expression of heme oxygenase-1, hypoxia inducible factor-1alpha, and ubiquitin in peripheral inflammatory cells from patients with coronary heart disease.
|
| |
Clin Chem Lab Med, 47,
327-333.
|
 |
|
|
|
|
 |
W.Xiao,
J.Ai,
G.Habermacher,
O.Volpert,
X.Yang,
A.Y.Zhang,
J.Hahn,
X.Cai,
and
Z.Wang
(2009).
U19/Eaf2 binds to and stabilizes von hippel-lindau protein.
|
| |
Cancer Res, 69,
2599-2606.
|
 |
|
|
|
|
 |
Y.Q.Tang,
B.M.Han,
X.Q.Yao,
Y.Hong,
Y.Wang,
F.J.Zhao,
S.Q.Yu,
X.W.Sun,
and
S.J.Xia
(2009).
Chimeric molecules facilitate the degradation of androgen receptors and repress the growth of LNCaP cells.
|
| |
Asian J Androl, 11,
119-126.
|
 |
|
|
|
|
 |
A.Klein,
D.Flügel,
and
T.Kietzmann
(2008).
Transcriptional regulation of serine/threonine kinase-15 (STK15) expression by hypoxia and HIF-1.
|
| |
Mol Biol Cell, 19,
3667-3675.
|
 |
|
|
|
|
 |
C.T.Supuran
(2008).
Carbonic anhydrases: novel therapeutic applications for inhibitors and activators.
|
| |
Nat Rev Drug Discov, 7,
168-181.
|
 |
|
|
|
|
 |
D.R.Mole,
and
P.J.Ratcliffe
(2008).
Cellular oxygen sensing in health and disease.
|
| |
Pediatr Nephrol, 23,
681-694.
|
 |
|
|
|
|
 |
F.S.Lee
(2008).
Genetic causes of erythrocytosis and the oxygen-sensing pathway.
|
| |
Blood Rev, 22,
321-332.
|
 |
|
|
|
|
 |
J.Ben-Shoshan,
S.Maysel-Auslender,
A.Mor,
G.Keren,
and
J.George
(2008).
Hypoxia controls CD4+CD25+ regulatory T-cell homeostasis via hypoxia-inducible factor-1alpha.
|
| |
Eur J Immunol, 38,
2412-2418.
|
 |
|
|
|
|
 |
J.Liu,
and
R.Nussinov
(2008).
Allosteric effects in the marginally stable von Hippel-Lindau tumor suppressor protein and allostery-based rescue mutant design.
|
| |
Proc Natl Acad Sci U S A, 105,
901-906.
|
 |
|
|
|
|
 |
J.Sudhamsu,
G.I.Lee,
D.F.Klessig,
and
B.R.Crane
(2008).
The Structure of YqeH: AN AtNOS1/AtNOA1 ORTHOLOG THAT COUPLES GTP HYDROLYSIS TO MOLECULAR RECOGNITION.
|
| |
J Biol Chem, 283,
32968-32976.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
K.Salnikow,
and
A.Zhitkovich
(2008).
Genetic and epigenetic mechanisms in metal carcinogenesis and cocarcinogenesis: nickel, arsenic, and chromium.
|
| |
Chem Res Toxicol, 21,
28-44.
|
 |
|
|
|
|
 |
M.D.Petroski
(2008).
The ubiquitin system, disease, and drug discovery.
|
| |
BMC Biochem, 9,
S7.
|
 |
|
|
|
|
 |
M.Fuxreiter,
P.Tompa,
I.Simon,
V.N.Uversky,
J.C.Hansen,
and
F.J.Asturias
(2008).
Malleable machines take shape in eukaryotic transcriptional regulation.
|
| |
Nat Chem Biol, 4,
728-737.
|
 |
|
|
|
|
 |
M.J.Percy,
P.A.Beer,
G.Campbell,
A.W.Dekker,
A.R.Green,
D.Oscier,
M.G.Rainey,
R.van Wijk,
M.Wood,
T.R.Lappin,
M.F.McMullin,
and
F.S.Lee
(2008).
Novel exon 12 mutations in the HIF2A gene associated with erythrocytosis.
|
| |
Blood, 111,
5400-5402.
|
 |
|
|
|
|
 |
M.L.Alcaide-German,
A.Vara-Vega,
L.F.Garcia-Fernandez,
M.O.Landazuri,
and
L.del Peso
(2008).
A yeast three-hybrid system that reconstitutes mammalian hypoxia inducible factor regulatory machinery.
|
| |
BMC Cell Biol, 9,
18.
|
 |
|
|
|
|
 |
P.P.Kapitsinou,
and
V.H.Haase
(2008).
The VHL tumor suppressor and HIF: insights from genetic studies in mice.
|
| |
Cell Death Differ, 15,
650-659.
|
 |
|
|
|
|
 |
R.Rajasekaran,
C.Sudandiradoss,
C.George Priya Doss,
A.Singh,
and
R.Sethumadhavan
(2008).
Computational detection of deleterious SNPs and their effect on sequence and structural level of the VHL gene.
|
| |
Mamm Genome, 19,
654-661.
|
 |
|
|
|
|
 |
S.Elliott
(2008).
Erythropoiesis-stimulating agents and other methods to enhance oxygen transport.
|
| |
Br J Pharmacol, 154,
529-541.
|
 |
|
|
|
|
 |
T.Ravid,
and
M.Hochstrasser
(2008).
Diversity of degradation signals in the ubiquitin-proteasome system.
|
| |
Nat Rev Mol Cell Biol, 9,
679-690.
|
 |
|
|
|
|
 |
A.Grosfeld,
I.P.Stolze,
M.E.Cockman,
C.W.Pugh,
M.Edelmann,
B.Kessler,
A.N.Bullock,
P.J.Ratcliffe,
and
N.Masson
(2007).
Interaction of hydroxylated collagen IV with the von hippel-lindau tumor suppressor.
|
| |
J Biol Chem, 282,
13264-13269.
|
 |
|
|
|
|
 |
A.Ozer,
and
R.K.Bruick
(2007).
Non-heme dioxygenases: cellular sensors and regulators jelly rolled into one?
|
| |
Nat Chem Biol, 3,
144-153.
|
 |
|
|
|
|
 |
B.T.Dye,
and
B.A.Schulman
(2007).
Structural mechanisms underlying posttranslational modification by ubiquitin-like proteins.
|
| |
Annu Rev Biophys Biomol Struct, 36,
131-150.
|
 |
|
|
|
|
 |
C.Bex,
K.Knauth,
S.Dambacher,
and
A.Buchberger
(2007).
A yeast two-hybrid system reconstituting substrate recognition of the von Hippel-Lindau tumor suppressor protein.
|
| |
Nucleic Acids Res, 35,
e142.
|
 |
|
|
|
|
 |
C.T.Taylor,
and
S.P.Colgan
(2007).
Hypoxia and gastrointestinal disease.
|
| |
J Mol Med, 85,
1295-1300.
|
 |
|
|
|
|
 |
E.H.Chew,
and
T.Hagen
(2007).
Substrate-mediated regulation of cullin neddylation.
|
| |
J Biol Chem, 282,
17032-17040.
|
 |
|
|
|
|
 |
J.Köditz,
J.Nesper,
M.Wottawa,
D.P.Stiehl,
G.Camenisch,
C.Franke,
J.Myllyharju,
R.H.Wenger,
and
D.M.Katschinski
(2007).
Oxygen-dependent ATF-4 stability is mediated by the PHD3 oxygen sensor.
|
| |
Blood, 110,
3610-3617.
|
 |
|
|
|
|
 |
J.W.Kim,
P.Gao,
Y.C.Liu,
G.L.Semenza,
and
C.V.Dang
(2007).
Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1.
|
| |
Mol Cell Biol, 27,
7381-7393.
|
 |
|
|
|
|
 |
J.W.Lee,
J.A.Park,
S.H.Kim,
J.H.Seo,
K.J.Lim,
J.W.Jeong,
C.H.Jeong,
K.H.Chun,
S.K.Lee,
Y.G.Kwon,
and
K.W.Kim
(2007).
Protein kinase C-delta regulates the stability of hypoxia-inducible factor-1 alpha under hypoxia.
|
| |
Cancer Sci, 98,
1476-1481.
|
 |
|
|
|
|
 |
L.Li,
L.Zhang,
X.Zhang,
Q.Yan,
Y.A.Minamishima,
A.F.Olumi,
M.Mao,
S.Bartz,
and
W.G.Kaelin
(2007).
Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations.
|
| |
Mol Cell Biol, 27,
5381-5392.
|
 |
|
|
|
|
 |
M.Winner,
L.Leng,
W.Zundel,
and
R.A.Mitchell
(2007).
Macrophage migration inhibitory factor manipulation and evaluation in tumoral hypoxic adaptation.
|
| |
Methods Enzymol, 435,
355-369.
|
 |
|
|
|
|
 |
N.S.Chandel,
and
G.R.Budinger
(2007).
The cellular basis for diverse responses to oxygen.
|
| |
Free Radic Biol Med, 42,
165-174.
|
 |
|
|
|
|
 |
P.G.Corn
(2007).
Role of the ubiquitin proteasome system in renal cell carcinoma.
|
| |
BMC Biochem, 8,
S4.
|
 |
|
|
|
|
 |
T.Schlesinger,
B.Appukuttan,
T.Hwang,
L.O.Atchaneeyakasul,
C.C.Chan,
Z.Zhuang,
J.T.Stout,
and
D.J.Wilson
(2007).
Internal en bloc resection and genetic analysis of retinal capillary hemangioblastoma.
|
| |
Arch Ophthalmol, 125,
1189-1193.
|
 |
|
|
|
|
 |
W.G.Kaelin
(2007).
Von hippel-lindau disease.
|
| |
Annu Rev Pathol, 2,
145-173.
|
 |
|
|
|
|
 |
Y.Chen
(2007).
The enzymes in ubiquitin-like post-translational modifications.
|
| |
Biosci Trends, 1,
16-25.
|
 |
|
|
|
|
 |
Y.Pan,
K.D.Mansfield,
C.C.Bertozzi,
V.Rudenko,
D.A.Chan,
A.J.Giaccia,
and
M.C.Simon
(2007).
Multiple factors affecting cellular redox status and energy metabolism modulate hypoxia-inducible factor prolyl hydroxylase activity in vivo and in vitro.
|
| |
Mol Cell Biol, 27,
912-925.
|
 |
|
|
|
|
 |
A.A.Qutub,
and
A.S.Popel
(2006).
A computational model of intracellular oxygen sensing by hypoxia-inducible factor HIF1 alpha.
|
| |
J Cell Sci, 119,
3467-3480.
|
 |
|
|
|
|
 |
A.Hergovich,
J.Lisztwan,
C.R.Thoma,
C.Wirbelauer,
R.E.Barry,
and
W.Krek
(2006).
Priming-dependent phosphorylation and regulation of the tumor suppressor pVHL by glycogen synthase kinase 3.
|
| |
Mol Cell Biol, 26,
5784-5796.
|
 |
|
|
|
|
 |
A.R.Kinderlerer,
R.Steinberg,
M.Johns,
S.K.Harten,
E.A.Lidington,
D.O.Haskard,
P.H.Maxwell,
and
J.C.Mason
(2006).
Statin-induced expression of CD59 on vascular endothelium in hypoxia: a potential mechanism for the anti-inflammatory actions of statins in rheumatoid arthritis.
|
| |
Arthritis Res Ther, 8,
R130.
|
 |
|
|
|
|
 |
E.P.Cummins,
E.Berra,
K.M.Comerford,
A.Ginouves,
K.T.Fitzgerald,
F.Seeballuck,
C.Godson,
J.E.Nielsen,
P.Moynagh,
J.Pouyssegur,
and
C.T.Taylor
(2006).
Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity.
|
| |
Proc Natl Acad Sci U S A, 103,
18154-18159.
|
 |
|
|
|
|
 |
G.Nalepa,
M.Rolfe,
and
J.W.Harper
(2006).
Drug discovery in the ubiquitin-proteasome system.
|
| |
Nat Rev Drug Discov, 5,
596-613.
|
 |
|
|
|
|
 |
J.Pouysségur,
and
F.Mechta-Grigoriou
(2006).
Redox regulation of the hypoxia-inducible factor.
|
| |
Biol Chem, 387,
1337-1346.
|
 |
|
|
|
|
 |
K.Knauth,
C.Bex,
P.Jemth,
and
A.Buchberger
(2006).
Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1alpha interactions.
|
| |
Oncogene, 25,
370-377.
|
 |
|
|
|
|
 |
M.A.McDonough,
V.Li,
E.Flashman,
R.Chowdhury,
C.Mohr,
B.M.Liénard,
J.Zondlo,
N.J.Oldham,
I.J.Clifton,
J.Lewis,
L.A.McNeill,
R.J.Kurzeja,
K.S.Hewitson,
E.Yang,
S.Jordan,
R.S.Syed,
and
C.J.Schofield
(2006).
Cellular oxygen sensing: Crystal structure of hypoxia-inducible factor prolyl hydroxylase (PHD2).
|
| |
Proc Natl Acad Sci U S A, 103,
9814-9819.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
N.A.Baird,
D.W.Turnbull,
and
E.A.Johnson
(2006).
Induction of the heat shock pathway during hypoxia requires regulation of heat shock factor by hypoxia-inducible factor-1.
|
| |
J Biol Chem, 281,
38675-38681.
|
 |
|
|
|
|
 |
P.H.Patel,
R.S.Chaganti,
and
R.J.Motzer
(2006).
Targeted therapy for metastatic renal cell carcinoma.
|
| |
Br J Cancer, 94,
614-619.
|
 |
|
|
|
|
 |
P.Koivunen,
M.Hirsilä,
K.I.Kivirikko,
and
J.Myllyharju
(2006).
The length of peptide substrates has a marked effect on hydroxylation by the hypoxia-inducible factor prolyl 4-hydroxylases.
|
| |
J Biol Chem, 281,
28712-28720.
|
 |
|
|
|
|
 |
R.N.de Jong,
E.Ab,
T.Diercks,
V.Truffault,
M.Daniëls,
R.Kaptein,
and
G.E.Folkers
(2006).
Solution structure of the human ubiquitin-specific protease 15 DUSP domain.
|
| |
J Biol Chem, 281,
5026-5031.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
S.C.Lo,
X.Li,
M.T.Henzl,
L.J.Beamer,
and
M.Hannink
(2006).
Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling.
|
| |
EMBO J, 25,
3605-3617.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
Z.Khan,
G.K.Michalopoulos,
and
D.B.Stolz
(2006).
Peroxisomal localization of hypoxia-inducible factors and hypoxia-inducible factor regulatory hydroxylases in primary rat hepatocytes exposed to hypoxia-reoxygenation.
|
| |
Am J Pathol, 169,
1251-1269.
|
 |
|
|
|
|
 |
C.T.Walsh,
S.Garneau-Tsodikova,
and
G.J.Gatto
(2005).
Protein posttranslational modifications: the chemistry of proteome diversifications.
|
| |
Angew Chem Int Ed Engl, 44,
7342-7372.
|
 |
|
|
|
|
 |
F.Miller,
A.Kentsis,
R.Osman,
and
Z.Q.Pan
(2005).
Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL.hypoxia-inducible transcription factor-1alpha complex.
|
| |
J Biol Chem, 280,
7985-7996.
|
 |
|
|
|
|
 |
H.J.Dyson,
and
P.E.Wright
(2005).
Intrinsically unstructured proteins and their functions.
|
| |
Nat Rev Mol Cell Biol, 6,
197-208.
|
 |
|
|
|
|
 |
J.L.Formento,
E.Berra,
B.Ferrua,
N.Magné,
G.Simos,
C.Brahimi-Horn,
J.Pouysségur,
and
G.Milano
(2005).
Enzyme-linked immunosorbent assay for pharmacological studies targeting hypoxia-inducible factor 1alpha.
|
| |
Clin Diagn Lab Immunol, 12,
660-664.
|
 |
|
|
|
|
 |
J.L.Ruas,
and
L.Poellinger
(2005).
Hypoxia-dependent activation of HIF into a transcriptional regulator.
|
| |
Semin Cell Dev Biol, 16,
514-522.
|
 |
|
|
|
|
 |
J.S.Isaacs,
Y.J.Jung,
D.R.Mole,
S.Lee,
C.Torres-Cabala,
Y.L.Chung,
M.Merino,
J.Trepel,
B.Zbar,
J.Toro,
P.J.Ratcliffe,
W.M.Linehan,
and
L.Neckers
(2005).
HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability.
|
| |
Cancer Cell, 8,
143-153.
|
 |
|
|
|
|
 |
J.S.Schneekloth,
and
C.M.Crews
(2005).
Chemical approaches to controlling intracellular protein degradation.
|
| |
Chembiochem, 6,
40-46.
|
 |
|
|
|
|
 |
K.Salnikow,
and
K.S.Kasprzak
(2005).
Ascorbate depletion: a critical step in nickel carcinogenesis?
|
| |
Environ Health Perspect, 113,
577-584.
|
 |
|
|
|
|
 |
M.A.Selak,
S.M.Armour,
E.D.MacKenzie,
H.Boulahbel,
D.G.Watson,
K.D.Mansfield,
Y.Pan,
M.C.Simon,
C.B.Thompson,
and
E.Gottlieb
(2005).
Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase.
|
| |
Cancer Cell, 7,
77-85.
|
 |
|
|
|
|
 |
M.Ogura,
T.Shibata,
J.Yi,
J.Liu,
R.Qu,
H.Harada,
and
M.Hiraoka
(2005).
A tumor-specific gene therapy strategy targeting dysregulation of the VHL/HIF pathway in renal cell carcinomas.
|
| |
Cancer Sci, 96,
288-294.
|
 |
|
|
|
|
 |
N.Sánchez-Puig,
D.B.Veprintsev,
and
A.R.Fersht
(2005).
Binding of natively unfolded HIF-1alpha ODD domain to p53.
|
| |
Mol Cell, 17,
11-21.
|
 |
|
|
|
|
 |
P.J.Stogios,
G.S.Downs,
J.J.Jauhal,
S.K.Nandra,
and
G.G.Privé
(2005).
Sequence and structural analysis of BTB domain proteins.
|
| |
Genome Biol, 6,
R82.
|
 |
|
|
|
|
 |
R.R.Raval,
K.W.Lau,
M.G.Tran,
H.M.Sowter,
S.J.Mandriota,
J.L.Li,
C.W.Pugh,
P.H.Maxwell,
A.L.Harris,
and
P.J.Ratcliffe
(2005).
Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma.
|
| |
Mol Cell Biol, 25,
5675-5686.
|
 |
|
|
|
|
 |
V.H.Haase
(2005).
The VHL tumor suppressor in development and disease: functional studies in mice by conditional gene targeting.
|
| |
Semin Cell Dev Biol, 16,
564-574.
|
 |
|
|
|
|
 |
W.G.Kaelin
(2005).
Proline hydroxylation and gene expression.
|
| |
Annu Rev Biochem, 74,
115-128.
|
 |
|
|
|
|
 |
W.G.Kaelin
(2005).
The von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing.
|
| |
Cold Spring Harb Symp Quant Biol, 70,
159-166.
|
 |
|
|
|
|
 |
Y.Jiang,
Z.H.Xue,
W.Z.Shen,
K.M.Du,
H.Yan,
Y.Yu,
Z.G.Peng,
M.G.Song,
J.H.Tong,
Z.Chen,
Y.Huang,
M.Lübbert,
and
G.Q.Chen
(2005).
Desferrioxamine induces leukemic cell differentiation potentially by hypoxia-inducible factor-1 alpha that augments transcriptional activity of CCAAT/enhancer-binding protein-alpha.
|
| |
Leukemia, 19,
1239-1247.
|
 |
|
|
|
|
 |
C.J.Schofield,
and
P.J.Ratcliffe
(2004).
Oxygen sensing by HIF hydroxylases.
|
| |
Nat Rev Mol Cell Biol, 5,
343-354.
|
 |
|
|
|
|
 |
C.P.Pavlovich,
and
L.S.Schmidt
(2004).
Searching for the hereditary causes of renal-cell carcinoma.
|
| |
Nat Rev Cancer, 4,
381-393.
|
 |
|
|
|
|
 |
D.Li,
M.Hirsilä,
P.Koivunen,
M.C.Brenner,
L.Xu,
C.Yang,
K.I.Kivirikko,
and
J.Myllyharju
(2004).
Many amino acid substitutions in a hypoxia-inducible transcription factor (HIF)-1alpha-like peptide cause only minor changes in its hydroxylation by the HIF prolyl 4-hydroxylases: substitution of 3,4-dehydroproline or azetidine-2-carboxylic acid for the proline leads to a high rate of uncoupled 2-oxoglutarate decarboxylation.
|
| |
J Biol Chem, 279,
55051-55059.
|
 |
|
|
|
|
 |
F.R.Sharp,
and
M.Bernaudin
(2004).
HIF1 and oxygen sensing in the brain.
|
| |
Nat Rev Neurosci, 5,
437-448.
|
 |
|
|
|
|
 |
F.R.Sharp,
R.Ran,
A.Lu,
Y.Tang,
K.I.Strauss,
T.Glass,
T.Ardizzone,
and
M.Bernaudin
(2004).
Hypoxic preconditioning protects against ischemic brain injury.
|
| |
NeuroRx, 1,
26-35.
|
 |
|
|
|
|
 |
K.S.Hewitson,
and
C.J.Schofield
(2004).
The HIF pathway as a therapeutic target.
|
| |
Drug Discov Today, 9,
704-711.
|
 |
|
|
|
|
 |
L.Bemis,
D.A.Chan,
C.V.Finkielstein,
L.Qi,
P.D.Sutphin,
X.Chen,
K.Stenmark,
A.J.Giaccia,
and
W.Zundel
(2004).
Distinct aerobic and hypoxic mechanisms of HIF-alpha regulation by CSN5.
|
| |
Genes Dev, 18,
739-744.
|
 |
|
|
|
|
 |
M.F.Czyzyk-Krzeska,
and
J.Meller
(2004).
von Hippel-Lindau tumor suppressor: not only HIF's executioner.
|
| |
Trends Mol Med, 10,
146-149.
|
 |
|
|
|
|
 |
M.Jansen,
P.C.de Witt Hamer,
A.N.Witmer,
D.Troost,
and
C.J.van Noorden
(2004).
Current perspectives on antiangiogenesis strategies in the treatment of malignant gliomas.
|
| |
Brain Res Brain Res Rev, 45,
143-163.
|
 |
|
|
|
|
 |
S.Ruiz-Llorente,
J.Bravo,
A.Cebrián,
A.Cascón,
M.Pollan,
D.Tellería,
R.Letón,
M.Urioste,
R.Rodríguez-López,
J.M.de Campos,
M.J.Muñoz,
C.Lacambra,
J.Benítez,
and
M.Robledo
(2004).
Genetic characterization and structural analysis of VHL Spanish families to define genotype-phenotype correlations.
|
| |
Hum Mutat, 23,
160-169.
|
 |
|
|
|
|
 |
S.S.Hong,
H.Lee,
and
K.W.Kim
(2004).
HIF-1alpha: a valid therapeutic target for tumor therapy.
|
| |
Cancer Res Treat, 36,
343-353.
|
 |
|
|
|
|
 |
T.Cardozo,
and
M.Pagano
(2004).
The SCF ubiquitin ligase: insights into a molecular machine.
|
| |
Nat Rev Mol Cell Biol, 5,
739-751.
|
 |
|
|
|
|
 |
T.Kong,
H.K.Eltzschig,
J.Karhausen,
S.P.Colgan,
and
C.S.Shelley
(2004).
Leukocyte adhesion during hypoxia is mediated by HIF-1-dependent induction of beta2 integrin gene expression.
|
| |
Proc Natl Acad Sci U S A, 101,
10440-10445.
|
 |
|
|
|
|
 |
Y.C.Liu
(2004).
Ubiquitin ligases and the immune response.
|
| |
Annu Rev Immunol, 22,
81.
|
 |
|
|
|
|
 |
A.V.Kuznetsova,
J.Meller,
P.O.Schnell,
J.A.Nash,
M.L.Ignacak,
Y.Sanchez,
J.W.Conaway,
R.C.Conaway,
and
M.F.Czyzyk-Krzeska
(2003).
von Hippel-Lindau protein binds hyperphosphorylated large subunit of RNA polymerase II through a proline hydroxylation motif and targets it for ubiquitination.
|
| |
Proc Natl Acad Sci U S A, 100,
2706-2711.
|
 |
|
|
|
|
 |
D.Lando,
J.J.Gorman,
M.L.Whitelaw,
and
D.J.Peet
(2003).
Oxygen-dependent regulation of hypoxia-inducible factors by prolyl and asparaginyl hydroxylation.
|
| |
Eur J Biochem, 270,
781-790.
|
 |
|
|
|
|
 |
E.Metzen,
J.Zhou,
W.Jelkmann,
J.Fandrey,
and
B.Brüne
(2003).
Nitric oxide impairs normoxic degradation of HIF-1alpha by inhibition of prolyl hydroxylases.
|
| |
Mol Biol Cell, 14,
3470-3481.
|
 |
|
|
|
|
 |
E.S.Hanson,
M.L.Rawlins,
and
E.A.Leibold
(2003).
Oxygen and iron regulation of iron regulatory protein 2.
|
| |
J Biol Chem, 278,
40337-40342.
|
 |
|
|
|
|
 |
G.L.Semenza
(2003).
Targeting HIF-1 for cancer therapy.
|
| |
Nat Rev Cancer, 3,
721-732.
|
 |
|
|
|
|
 |
G.Wu,
G.Xu,
B.A.Schulman,
P.D.Jeffrey,
J.W.Harper,
and
N.P.Pavletich
(2003).
Structure of a beta-TrCP1-Skp1-beta-catenin complex: destruction motif binding and lysine specificity of the SCF(beta-TrCP1) ubiquitin ligase.
|
| |
Mol Cell, 11,
1445-1456.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
J.A.Straub,
E.A.Lipscomb,
E.S.Yoshida,
and
R.S.Freeman
(2003).
Induction of SM-20 in PC12 cells leads to increased cytochrome c levels, accumulation of cytochrome c in the cytosol, and caspase-dependent cell death.
|
| |
J Neurochem, 85,
318-328.
|
 |
|
|
|
|
 |
J.M.Elkins,
K.S.Hewitson,
L.A.McNeill,
J.F.Seibel,
I.Schlemminger,
C.W.Pugh,
P.J.Ratcliffe,
and
C.J.Schofield
(2003).
Structure of factor-inhibiting hypoxia-inducible factor (HIF) reveals mechanism of oxidative modification of HIF-1 alpha.
|
| |
J Biol Chem, 278,
1802-1806.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
L.E.Huang,
and
H.F.Bunn
(2003).
Hypoxia-inducible factor and its biomedical relevance.
|
| |
J Biol Chem, 278,
19575-19578.
|
 |
|
|
|
|
 |
M.Hirsilä,
P.Koivunen,
V.Günzler,
K.I.Kivirikko,
and
J.Myllyharju
(2003).
Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor.
|
| |
J Biol Chem, 278,
30772-30780.
|
 |
|
|
|
|
 |
M.J.Percy,
S.M.Mooney,
M.F.McMullin,
A.Flores,
T.R.Lappin,
and
F.S.Lee
(2003).
A common polymorphism in the oxygen-dependent degradation (ODD) domain of hypoxia inducible factor-1alpha (HIF-1alpha) does not impair Pro-564 hydroxylation.
|
| |
Mol Cancer, 2,
31.
|
 |
|
|
|
|
 |
M.Safran,
and
W.G.Kaelin
(2003).
HIF hydroxylation and the mammalian oxygen-sensing pathway.
|
| |
J Clin Invest, 111,
779-783.
|
 |
|
|
|
|
 |
N.Goda,
S.J.Dozier,
and
R.S.Johnson
(2003).
HIF-1 in cell cycle regulation, apoptosis, and tumor progression.
|
| |
Antioxid Redox Signal, 5,
467-473.
|
 |
|
|
|
|
 |
P.G.Corn,
E.R.McDonald,
J.G.Herman,
and
W.S.El-Deiry
(2003).
Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau protein.
|
| |
Nat Genet, 35,
229-237.
|
 |
|
|
|
|
 |
R.L.Rich,
and
D.G.Myszka
(2003).
A survey of the year 2002 commercial optical biosensor literature.
|
| |
J Mol Recognit, 16,
351-382.
|
 |
|
|
|
|
 |
S.J.Freedman,
Z.Y.Sun,
A.L.Kung,
D.S.France,
G.Wagner,
and
M.J.Eck
(2003).
Structural basis for negative regulation of hypoxia-inducible factor-1alpha by CITED2.
|
| |
Nat Struct Biol, 10,
504-512.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
S.Richard
(2003).
von Hippel-Lindau disease: recent advances and therapeutic perspectives.
|
| |
Expert Rev Anticancer Ther, 3,
215-233.
|
 |
|
|
|
|
 |
T.Pawson,
and
P.Nash
(2003).
Assembly of cell regulatory systems through protein interaction domains.
|
| |
Science, 300,
445-452.
|
 |
|
|
|
|
 |
T.Pereira,
X.Zheng,
J.L.Ruas,
K.Tanimoto,
and
L.Poellinger
(2003).
Identification of residues critical for regulation of protein stability and the transactivation function of the hypoxia-inducible factor-1alpha by the von Hippel-Lindau tumor suppressor gene product.
|
| |
J Biol Chem, 278,
6816-6823.
|
 |
|
|
|
|
 |
T.Schioppa,
B.Uranchimeg,
A.Saccani,
S.K.Biswas,
A.Doni,
A.Rapisarda,
S.Bernasconi,
S.Saccani,
M.Nebuloni,
L.Vago,
A.Mantovani,
G.Melillo,
and
A.Sica
(2003).
Regulation of the chemokine receptor CXCR4 by hypoxia.
|
| |
J Exp Med, 198,
1391-1402.
|
 |
|
|
|
|
 |
V.Y.Polotsky,
J.Li,
N.M.Punjabi,
A.E.Rubin,
P.L.Smith,
A.R.Schwartz,
and
C.P.O'Donnell
(2003).
Intermittent hypoxia increases insulin resistance in genetically obese mice.
|
| |
J Physiol, 552,
253-264.
|
 |
|
|
|
|
 |
W.Kim,
and
W.G.Kaelin
(2003).
The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer.
|
| |
Curr Opin Genet Dev, 13,
55-60.
|
 |
|
|
|
|
 |
G.L.Semenza
(2002).
Physiology meets biophysics: visualizing the interaction of hypoxia-inducible factor 1 alpha with p300 and CBP.
|
| |
Proc Natl Acad Sci U S A, 99,
11570-11572.
|
 |
|
|
|
|
 |
J.Huang,
Q.Zhao,
S.M.Mooney,
and
F.S.Lee
(2002).
Sequence determinants in hypoxia-inducible factor-1alpha for hydroxylation by the prolyl hydroxylases PHD1, PHD2, and PHD3.
|
| |
J Biol Chem, 277,
39792-39800.
|
 |
|
|
|
|
 |
L.E.Huang,
E.A.Pete,
M.Schau,
J.Milligan,
and
J.Gu
(2002).
Leu-574 of HIF-1alpha is essential for the von Hippel-Lindau (VHL)-mediated degradation pathway.
|
| |
J Biol Chem, 277,
41750-41755.
|
 |
|
|
|
|
 |
S.O.Ang,
H.Chen,
K.Hirota,
V.R.Gordeuk,
J.Jelinek,
Y.Guan,
E.Liu,
A.I.Sergueeva,
G.Y.Miasnikova,
D.Mole,
P.H.Maxwell,
D.W.Stockton,
G.L.Semenza,
and
J.T.Prchal
(2002).
Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia.
|
| |
Nat Genet, 32,
614-621.
|
 |
|
|
|
|
 |
W.G.Kaelin
(2002).
Molecular basis of the VHL hereditary cancer syndrome.
|
| |
Nat Rev Cancer, 2,
673-682.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
| |